Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.
Azalea Therapeutics has raised $65.0M in total funding. The most recent round was Series A. The last funding was announced in November 2025.
Azalea Therapeutics's investors include HS Chau Women in Enterprising Science program, RA Capital Management, Yosemite, Sozo Ventures, Third Rock Ventures.
Azalea Therapeutics is headquartered in Berkeley, United States.
Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.
Azalea Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Azalea Therapeutics — Funding & Investors." VCBacked, November 4, 2025, https://www.vcbacked.co/company/azalea-therapeutics. Accessed September 3, 2026.
VCBacked. (2025). Azalea Therapeutics — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/azalea-therapeutics
{{cite web |title=Azalea Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/azalea-therapeutics |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated